US CBP Launches 'Sterilization Systems' Targeted Examinations

Starting May 8, 2026, U.S. Customs and Border Protection (CBP) initiated a 90-day targeted examination of imported Sterilization Systems—including ethylene oxide (EO) sterilizers and hydrogen peroxide plasma devices—at the Los Angeles, New York, and Chicago ports of entry. This action directly affects medical device manufacturers, exporters, and importers supplying EO-processed equipment to the U.S. market, as it introduces a mandatory requirement for third-party EO residue testing—making timely clearance contingent on compliance.

Event Overview

On May 8, 2026, U.S. Customs and Border Protection (CBP) began a 90-day targeted examination program for imported Sterilization Systems at three major U.S. ports: Los Angeles, New York, and Chicago. The examination applies to equipment such as ethylene oxide (EO) sterilization chambers and hydrogen peroxide plasma sterilizers. All entries must be accompanied by a third-party test report verifying EO residue levels, issued by an ISO/IEC 17025-accredited laboratory and conducted in accordance with ISO 10993-7:2023. Shipments lacking this documentation are subject to full detention. Multiple export enterprises based in Guangdong and Jiangsu provinces have reported customs clearance delays of 14–21 days.

Industries Affected by Segment

Direct Exporters and Trading Companies

Exporters of Sterilization Systems face immediate operational impact: failure to submit compliant EO residue reports results in detention—not rejection—of entire shipments. This disrupts delivery schedules, triggers storage fees, and may breach contractual delivery terms with U.S. buyers.

Medical Device Manufacturers (OEM/ODM)

Manufacturers producing EO-based sterilizers—or integrating EO sterilization functionality into broader medical platforms—must now verify residue compliance not only for finished units but also for components that undergo EO processing during production. This adds upstream validation steps and potential rework cycles before shipment.

Contract Testing and Certification Service Providers

Laboratories accredited to ISO/IEC 17025—and specifically experienced in ISO 10993-7:2023 testing—are seeing increased demand for EO residue analysis. However, capacity constraints and turnaround time variability (especially for non-routine sample preparation) may limit scalability during the 90-day period.

Distribution and Import Agents

U.S.-based importers and customs brokers handling Sterilization Systems must now incorporate residue report verification into pre-entry checks. Absence of this step risks detention after arrival—shifting liability from the foreign shipper to the U.S. importer under CBP’s informed compliance framework.

Key Points for Enterprises and Practitioners

Monitor official CBP communications for scope clarification

CBP has not yet published formal guidance or a Federal Register notice detailing exemptions, transitional provisions, or applicability to refurbished or used equipment. Enterprises should track updates via CBP’s Trade Facilitation and Enforcement (TF&E) portal and official port bulletins.

Verify test report alignment with ISO 10993-7:2023 requirements

Not all EO residue reports meet the standard’s sampling methodology, detection limits (e.g., ≤ 2 µg/g for devices contacting intact skin), or reporting format. Enterprises should confirm that their lab explicitly cites ISO 10993-7:2023—and conducts testing on representative, fully assembled units where applicable.

Distinguish between policy signal and enforcement reality

Analysis shows this is a targeted, time-bound examination—not a permanent regulatory amendment. Its duration (90 days) and geographic focus (three ports) suggest CBP is assessing current compliance patterns rather than implementing a new rule. However, outcomes may inform future regulatory action.

Prepare documentation and logistics buffers ahead of shipment

Given reported delays of 14–21 days, exporters should allow minimum 30-day lead time between test completion and U.S. arrival. Retain digital and hard copies of lab reports, accreditation certificates, and chain-of-custody records for immediate submission upon request.

Editorial Perspective / Industry Observation

Observably, this initiative reflects heightened CBP attention to biocompatibility-related documentation for medical-grade equipment—not just finished devices, but supporting systems like sterilizers. While the measure is framed as an examination, its enforcement mechanism (detention without report submission) gives it practical weight equivalent to a compliance checkpoint. From an industry perspective, it signals growing convergence between customs enforcement and medical device quality system expectations—particularly around chemical residue verification. Current evidence does not indicate expansion beyond the three named ports or extension beyond the 90-day window, but sustained noncompliance rates could prompt broader application.

Conclusion

This CBP action is best understood not as a standalone regulatory change, but as a focused compliance stress test targeting documentation rigor in the sterilization equipment supply chain. Its significance lies less in introducing new legal obligations—and more in revealing how existing standards (ISO 10993-7:2023) are being operationally enforced at the border. For affected stakeholders, proactive verification, documentation readiness, and close monitoring of CBP’s next steps remain the most pragmatic responses.

Source Attribution

Main source: U.S. Customs and Border Protection (CBP) port-level enforcement notices issued May 8, 2026, for Los Angeles, New York, and Chicago field offices. Additional context drawn from verified incident reports from export enterprises in Guangdong and Jiangsu provinces. Ongoing developments—including potential extension, scope adjustments, or formal guidance—remain under observation.